Delirium

Delirium is an acute, fluctuating disturbance of attention and awareness accompanied by a change in cognition that develops over hours to days. It represents a medical emergency because it signals an underlying physiological derangement. DSM-5-TR classifies delirium under Neurocognitive Disorders and specifies five diagnostic criteria. References: DSM-5-TR, StatPearls (NCBI Bookshelf).

Delirium is an acute, fluctuating disturbance of attention and awareness accompanied by a change in cognition that develops over hours to days. It represents a medical emergency because it signals an underlying physiological derangement. DSM-5-TR classifies delirium under Neurocognitive Disorders and specifies five diagnostic criteria. Prevalence reaches 10-30% in hospitalised elderly patients and up to 80% in ICU patients. The condition remains dangerously underdiagnosed - studies estimate that 60% of cases are missed, particularly the hypoactive subtype. Delirium independently increases mortality, length of stay, institutionalisation, and long-term cognitive decline. ICD-11 classifies it under 6D70. This information is for psychoeducation only.

The hallmark is acute onset with fluctuating course. Symptoms wax and wane over the day, typically worsening at night ('sundowning'). Attention and awareness: patients cannot sustain, focus, or shift attention. They drift off mid-conversation, have difficulty following commands, and appear confused about their environment. Awareness of surroundings is reduced. Cognition: disorientation (time first, then place; person orientation is usually preserved until late stages), memory impairment (particularly recent memory), language disturbance (rambling, incoherent speech, word-finding difficulty), visuospatial dysfunction (cannot copy simple drawings or navigate familiar spaces). Psychomotor subtypes: (1) Hyperactive delirium (~25%): agitation, restlessness, pulling at lines/catheters, combativeness, hallucinations (typically visual - seeing insects, people, animals), paranoid delusions. This subtype is easy to detect but often misdiagnosed as psychosis. (2) Hypoactive delirium (~25-50%): somnolence, lethargy, reduced movement, quiet confusion, apathy. This is the most common and most dangerous subtype because it is frequently missed or mistaken for depression or fatigue. (3) Mixed delirium (~25-30%): alternates between hyperactive and hypoactive states. Sleep-wake cycle disruption: fragmented sleep, daytime somnolence, nocturnal agitation. Perceptual disturbances: visual hallucinations (most common), illusions (misinterpreting shadows as people), tactile hallucinations. Emotional lability: fear, anxiety, irritability, or apathy depending on subtype.

Predisposing factors (baseline vulnerability): advanced age (>70 years is the single strongest risk factor); pre-existing dementia (increases delirium risk 2-5 fold; present in 25-50% of delirium cases); prior delirium episode; multiple comorbidities (Charlson Comorbidity Index >=3); functional dependence; sensory impairment (vision, hearing);

malnutrition and dehydration; alcohol use disorder; baseline cognitive impairment (even mild). Precipitating factors (acute triggers): medications (anticholinergics are the single most common drug-related cause - diphenhydramine, oxybutynin, tricyclics; benzodiazepines; opioids; corticosteroids; polypharmacy); infection (urinary tract infection and pneumonia are the two most common infectious causes); surgery (incidence 15-50% after major surgery; hip fracture repair carries 35-65% risk); metabolic disturbances (hypoglycaemia, hyperglycaemia, hyponatraemia, hypercalcaemia, uraemia, hepatic encephalopathy); hypoxia; dehydration; urinary retention; constipation (often overlooked but can precipitate delirium in vulnerable patients); pain (both undertreated and overtreated); sleep deprivation; physical restraints; ICU environment; substance withdrawal (alcohol, benzodiazepines). The vulnerability-precipitant model explains why a minor trigger (constipation) can cause delirium in a highly vulnerable patient (elderly with dementia), while a healthy young adult requires a severe insult (sepsis, major surgery) to develop delirium.

Delirium is always caused by an identifiable physiological disturbance. Common causes by category: Infectious: UTI (the most common cause in elderly), pneumonia, sepsis, meningitis, encephalitis, COVID-19, cellulitis, intra-abdominal infection. Metabolic: electrolyte abnormalities (hyponatraemia is the most common), hypoglycaemia, hyperglycaemia/DKA/HHS, hypercalcaemia, uraemia, hepatic encephalopathy, thiamine deficiency (Wernicke encephalopathy), hypoxia, hypercarbia, acidosis. Drug-related: anticholinergic medications (use the Anticholinergic Burden Calculator at ACBcalc.com), benzodiazepines, opioids (especially meperidine), corticosteroids, fluoroquinolones, H2 blockers (especially cimetidine), polypharmacy (>=5 medications increases risk significantly), drug intoxication. Withdrawal: alcohol withdrawal (delirium tremens, onset 48-96 hours after last drink, mortality 5-15% untreated), benzodiazepine withdrawal, barbiturate withdrawal, opioid withdrawal (less commonly causes full delirium). Neurological: stroke, intracranial haemorrhage, seizures/postictal state, subdural haematoma, meningitis/encephalitis, brain metastases. Surgical/procedural: post-operative delirium (especially cardiac surgery, hip fracture repair), anaesthesia effects, pain, sleep disruption, ICU environment. Cardiac: myocardial infarction, heart failure, arrhythmia causing reduced cerebral perfusion. Other: urinary retention, faecal impaction, sensory deprivation, immobilisation, physical restraints. Often the cause is multifactorial - a typical case involves an elderly patient with baseline dementia (predisposing) who develops a UTI while taking anticholinergic medication (precipitating).

General population: 1-2%. Emergency department presentations: 8-17% of older adults; often missed. General medical inpatients at admission: 10-31%. During hospitalisation: 11-14% develop new delirium. Post-surgical: 15-53%, highest after hip fracture (35-65%) and cardiac surgery (20-50%). ICU: up to 80% of mechanically ventilated patients. Nursing homes and post-acute care: 20-22% prevalence. Age is the strongest demographic predictor. Patients >65 account for the majority of cases. Male sex confers slightly increased risk (OR ~1.3). Delirium occurs in 85% of patients at end of life (terminal delirium). In-hospital mortality: delirium increases the risk of death during hospitalisation 2-fold. Six-month mortality after a delirium episode: increased by 70% compared to non-delirious patients. ICU delirium: associated with a 2-4 fold increase in overall mortality. Each day of delirium in the ICU increases mortality risk by approximately 10%. Healthcare costs attributable to delirium: estimated at $164 billion annually in the USA.

Multiple mechanisms converge to produce the syndrome of delirium. No single pathway explains all cases, and multiple processes likely operate simultaneously. Neurotransmitter imbalance: the central finding is reduced cholinergic activity and increased dopaminergic activity. Acetylcholine (ACh) is essential for attention, arousal, and memory - anticholinergic drugs are the most common pharmacological cause of delirium precisely because they block ACh. Excess dopamine contributes to hallucinations, agitation, and psychomotor disturbance. The ACh-dopamine balance normally regulates alertness and cognition; disruption of this balance produces the core features of delirium. Neuroinflammation: systemic infection or surgery activates peripheral inflammatory mediators (IL-1, IL-6, TNF-alpha, interferon). These cytokines cross the blood-brain barrier (BBB) or signal through vagal afferents, activating microglia in the brain. Activated microglia release neurotoxic mediators that damage neurons, particularly in the hippocampus and cortex. The BBB itself becomes more permeable during systemic inflammation, worsening central neuroinflammation. Oxidative stress: the brain is highly vulnerable to reactive oxygen species (ROS) because of its high lipid content, high oxygen consumption, and limited antioxidant capacity. Metabolic derangements, hypoxia, and inflammation all increase ROS production, causing neuronal damage. Cortisol excess: physiological stress activates the HPA axis, raising cortisol levels. Elevated cortisol damages hippocampal neurons (which are rich in glucocorticoid receptors), impairs memory, and disrupts the sleep-wake cycle. Melatonin disruption: hospitalisation disrupts circadian rhythms, reducing melatonin secretion. Since melatonin regulates the sleep-wake cycle, antioxidant defence, and immune function, its disruption contributes to the nocturnal worsening ('sundowning') characteristic of delirium. Ageing: reduced cerebral blood flow, decreased neuronal density, diminished cholinergic reserve, and reduced physiological resilience all make the elderly brain more vulnerable to delirium-producing insults. Neurobiology in Simple Terms

Delirium occurs when the brain is overwhelmed by a medical insult (infection, medication, surgery, etc.). Acetylcholine—a chemical critical for attention, wakefulness, and memory—is often reduced (anticholinergic drugs block it). At the same time, dopamine can spike, contributing to confusion, hallucinations, and agitation. Inflammation from infection or surgery can cross into the brain and activate immune cells there, damaging neurons. Stress hormones (cortisol) rise and can harm memory circuits in the hippocampus. Disrupted sleep and circadian rhythms (common in hospital) further destabilise the brain. Older brains have fewer reserves and are more vulnerable. Delirium is a sign that the brain is struggling—treating the underlying cause (infection, stopping harmful drugs, correcting electrolytes) and providing a calm, orienting environment helps the brain recover.

Detection is the first and most important step. Delirium is missed in up to 60% of cases, particularly the hypoactive subtype. History: (1) Establish cognitive baseline - ask family/carers: 'What was the patient like before this hospital admission? Were they managing independently? Any known dementia?' (2) Timeline of change: acute onset (hours to days) distinguishes delirium from dementia (insidious onset over months). (3) Fluctuation: 'Does the confusion come and go? Are there lucid intervals?' (4) Recent medication changes: new additions, dose increases, or discontinuations - check for anticholinergics, benzodiazepines, opioids. (5) New symptoms: fever, cough, dysuria, pain, falls, reduced oral intake. (6) Substance use history: alcohol, benzodiazepines (assess withdrawal risk). (7) Sleep pattern: disrupted sleep-wake cycle is nearly universal in delirium. Physical examination: (1) Vital signs: fever (infection), tachycardia (sepsis, withdrawal, pain), hypotension (dehydration, sepsis), hypoxia (SpO2 <92%). (2) General: hydration status (mucous membranes, skin turgor, urine output), nutritional status. (3) Head/neck: nuchal rigidity (meningitis). (4) Cardiovascular: arrhythmia, signs of heart failure. (5) Respiratory: crackles (pneumonia), tachypnoea. (6) Abdominal: distension (constipation, retention), suprapubic fullness (urinary retention), tenderness. (7) Neurological: level of consciousness, focal deficits (stroke), asterixis (hepatic encephalopathy), tremor (withdrawal), pupil size (opioid intoxication: miotic; anticholinergic: mydriatic). (8) Skin: pressure ulcers, cellulitis, rashes.

DSM-5-TR specifies 5 criteria, all of which must be met: A. A disturbance in attention (reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment). B. The disturbance develops over a short period (usually hours to a few days), represents a change from baseline, and tends to fluctuate in severity during the course of the day. C. An additional disturbance in cognition (memory deficit, disorientation, language, visuospatial ability, or perception). D. The disturbances in Criteria A and C are not better explained by another pre-existing, established, or evolving neurocognitive disorder and do not occur in the context of a severely reduced level of arousal such as coma. E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal, or exposure to a toxin, or is due to multiple aetiologies.

Specify if: substance intoxication delirium; substance withdrawal delirium; medication-induced delirium; delirium due to another medical condition; delirium due to multiple aetiologies. Specify: acute (hours to days) vs. persistent (weeks to months). Specify: hyperactive, hypoactive, or mixed level of activity. ICD-11 code: 6D70 (Delirium). Additional codes specify aetiology (e.g., delirium due to disease classified elsewhere, substance-induced delirium). The CAM (Confusion Assessment Method) operationalises the DSM criteria into a rapid bedside screening tool with 94-100% sensitivity and 90-95% specificity. CAM requires: (1) acute onset with fluctuating course AND (2) inattention AND either (3) disorganised thinking OR (4) altered level of consciousness.

Screening tools: CAM (Confusion Assessment Method) is the most widely used and validated. CAM-ICU adapts CAM for nonverbal/ventilated patients using visual attention tasks (sensitivity 80%, specificity 96%). 3D-CAM provides a structured, brief version for general medical settings. 4AT (rapid 4-item screening) takes under 2 minutes and does not require training. Delirium Rating Scale-Revised-98 (DRS-R-98) provides a detailed severity rating with 16 items. Once delirium is identified, the priority is finding the underlying cause. Standard evaluation: Blood tests: CBC (infection, anaemia), BMP/CMP (electrolytes, glucose, renal function, hepatic function), calcium, magnesium, phosphate, thyroid function (TSH, free T4), arterial blood gas if hypoxia suspected, blood cultures if febrile, ammonia level if hepatic encephalopathy suspected, B12 and folate, cortisol if adrenal pathology suspected. Urinalysis and urine culture: UTI is the most common infectious cause in the elderly. Chest X-ray: pneumonia screening. ECG: arrhythmia, QTc measurement (baseline before starting antipsychotics). Medication review: use the Beers Criteria (AGS 2019) and Anticholinergic Burden Calculator to identify offending medications. Additional investigations as indicated: CT head (if focal neurological deficits, history of fall, anticoagulation, suspected intracranial pathology), lumbar puncture (if meningitis/encephalitis suspected), EEG (if non-convulsive status epilepticus suspected - shows generalised slowing in delirium, which can help distinguish from psychiatric conditions).

Dementia: insidious onset over months to years; attention is relatively preserved until late stages; stable (not fluctuating) day to day; level of consciousness is normal until late stages. Delirium frequently superimposes on dementia, and distinguishing the two requires knowing the patient's cognitive baseline. Key question: 'Was this confusion present before admission, or is it new?'

Depression (especially in elderly): psychomotor retardation, apathy, and poor concentration can mimic hypoactive delirium. Depression develops over weeks, not hours/days. Attention is intact on formal testing. No perceptual disturbances. Psychotic disorders (schizophrenia, brief psychotic episode): auditory hallucinations predominate (visual hallucinations strongly suggest delirium). Attention is intact in primary psychosis. No fluctuating level of consciousness. Schizophrenia has a typical onset age of late teens to 20s and a chronic course. Non-convulsive status epilepticus (NCSE): can closely mimic delirium with altered consciousness, confusion, and subtle motor findings (eye deviation, facial twitching). EEG is diagnostic. Should be suspected in any delirium that does not improve with standard management or in patients with seizure history. Substance intoxication/withdrawal: can itself cause delirium (and is classified as a subtype of delirium). Always obtain a detailed substance use history and drug screen. Alcohol withdrawal delirium (delirium tremens) typically begins 48-96 hours after the last drink and includes autonomic instability, tremor, agitation, and seizures. Sundowning in dementia: evening agitation in dementia patients can mimic delirium but is typically a predictable, nightly pattern without the acute onset and fluctuating attention deficits of delirium.

Treatment of Delirium requires identification and treatment of the underlying cause, supportive care, and symptomatic management. Identify and Treat the Underlying Cause: The most important step is identifying and correcting the precipitating factor(s). Common causes include infection (urinary tract infection, pneumonia, sepsis), metabolic disturbances (electrolyte imbalances, hypoglycaemia, renal or hepatic failure), medication effects (anticholinergics, opioids, benzodiazepines, polypharmacy), substance withdrawal (alcohol, benzodiazepines), dehydration, pain, urinary retention, constipation, and hypoxia. A thorough medical workup including blood tests, urinalysis, chest imaging, and medication review is essential. Stop or reduce offending medications whenever possible - this alone resolves many cases. Non-Pharmacological Management: Environmental modifications are first-line interventions: maintain a calm, well-lit environment with minimal stimulation; ensure adequate hydration and nutrition; promote sleep-wake cycle regulation (natural light during the day, quiet and dark at night); provide orientation cues (clocks, calendars, familiar objects); ensure hearing aids and glasses are available; encourage family presence; minimise unnecessary lines, catheters, and restraints; promote early mobilisation. Physical restraints worsen delirium - they increase agitation, injury risk, and duration of delirium. Pharmacological Management: Medications are reserved for patients who are severely agitated, distressed, or at risk of harming themselves or others. They do not treat the underlying cause and do not shorten delirium duration. Low-dose haloperidol (0.5-2mg PO/IM/IV every 4 hours as needed) is the most studied agent. Monitor QTc (IV haloperidol carries risk of QTc prolongation and torsades de pointes). Daily dose should not exceed 20mg in most cases.

Atypical antipsychotics: quetiapine (25-50mg, titrated to 100-200mg/day in divided doses), olanzapine (2.5-5mg nightly), risperidone (0.25-1mg) are alternatives with potentially fewer extrapyramidal side effects but still carry metabolic and cardiac risks. Benzodiazepines are generally avoided except in alcohol or benzodiazepine withdrawal delirium, where they are first-line (lorazepam 1-2mg IV/IM for alcohol withdrawal). In other forms of delirium, benzodiazepines typically worsen confusion. Dexmedetomidine (alpha-2 agonist) may be useful in ICU settings, especially for mechanically ventilated patients - it reduces delirium duration compared to benzodiazepine-based sedation. Melatonin (0.5-5mg at bedtime) or ramelteon (8mg) may help restore sleep-wake cycle disruption, though evidence is mixed. All medications should be used at the lowest effective dose for the shortest duration. The FDA black-box warning notes increased mortality risk with antipsychotic use in elderly patients with dementia-related psychosis. Prevention: The Hospital Elder Life Program (HELP) reduces delirium incidence by 40% in hospitalised older adults through targeted interventions: cognitive stimulation, sleep enhancement (warm milk, relaxation techniques, noise reduction), early mobilisation, hydration protocols, vision and hearing optimisation, and reorientation protocols. These multicomponent non-pharmacological programmes are the strongest evidence-based approach to delirium prevention.

Delirium was historically considered a transient, reversible condition. Current evidence shows it carries significant short- and long-term consequences. In-hospital mortality: 22-76% in hospitalised patients (compared to 1-25% in non-delirious matched controls). Each day of delirium in the ICU increases the risk of death at 1 year by approximately 10%. Duration: the median duration of a delirium episode varies from 2-5 days to several weeks. Hospital delirium persists until discharge in 45% of cases and for at least 1 month after discharge in 33%. Some patients develop persistent delirium lasting months, particularly those with underlying dementia. Long-term cognitive outcomes: delirium independently accelerates cognitive decline. Patients who experience delirium are 2-3 times more likely to develop dementia over the following years compared to matched controls who did not have delirium. This suggests delirium may directly damage the brain, not just unmask existing neurodegeneration. Functional outcomes: patients who experience delirium have higher rates of institutionalisation, loss of independence, and failure to return to baseline function. Approximately 60% of elderly patients who survive a delirium episode do not return to their pre-delirium functional level within 12 months.

Mortality: delirium is independently associated with a 2-fold increase in mortality in hospitalised patients. ICU delirium carries a 2-4 fold increased mortality risk. Delirium in end-of-life settings (terminal delirium) occurs in up to 85% of dying patients and creates significant distress for patients, families, and staff. Physical complications: falls (patients with delirium are at 6 times increased risk of falling during hospitalisation), pressure ulcers (immobility and reduced awareness), aspiration pneumonia (impaired swallowing and reduced consciousness), dehydration and malnutrition, prolonged intubation and ICU stay, hospital-acquired infections, and

injuries from pulling out lines, catheters, or tubes. Cognitive complications: accelerated cognitive decline, new-onset dementia, post-traumatic stress symptoms (20-50% of patients recall frightening hallucinations and delusional experiences from their delirium episode). Healthcare utilisation: delirium increases hospital length of stay by 5-10 days, increases ICU stay, increases likelihood of nursing home placement (OR 2.4), and generates an estimated $164 billion annually in additional healthcare costs in the USA. Psychological impact: both patients and families experience significant distress. Patients may have traumatic memories of hallucinations and confusion. Family members may interpret delirium as the patient 'going crazy' or dying, and may need support and education.

Prevention is the single most effective strategy against delirium. The Hospital Elder Life Program (HELP) reduces delirium incidence by approximately 40% through a standardised protocol: orientation (daily orientation boards, cognitive stimulation three times daily); sleep enhancement (warm drink at bedtime, relaxation music, noise reduction, minimise night-time observations and vital signs); early mobilisation (ambulation or range-of-motion exercises three times daily from day 1); hydration (encourage oral fluids, monitor intake/output); vision (ensure glasses are at bedside); hearing (ensure hearing aids are available, use amplification devices). Medication stewardship: review all medications at admission and throughout hospitalisation. Discontinue or reduce anticholinergics, benzodiazepines, and other high-risk drugs. Use the Beers Criteria and START/STOPP criteria to guide prescribing in elderly patients. Avoid adding new medications known to precipitate delirium. Patient and family education: delirium is a medical condition, not 'going crazy.' It is caused by an underlying medical problem. It is usually temporary but requires prompt investigation. Family presence at the bedside is one of the most effective non-pharmacological interventions. After discharge, watch for persistent confusion and report it to the medical team. Some patients will have distressing memories of the experience and may benefit from follow-up discussion.

Delirium is among the oldest recognised medical conditions. Hippocrates (5th century BCE) described 'phrenitis' (acute confusional states with fever) and 'lethargus' (hypoactive confusional states). The term 'delirium' derives from Latin 'delirare' (to go off the furrow/track) and was used by Celsus in the 1st century CE. For centuries, delirium was lumped with psychosis, mania, and 'madness.' 19th century: physicians began distinguishing acute reversible confusion from chronic dementia. Bonhoeffer (1910) described 'exogenous reaction types' - a limited set of behavioural patterns (confusion, hallucinations, agitation) produced by diverse medical causes. This was an early recognition that delirium represents a common final pathway of brain dysfunction.

20th century: DSM-I (1952) included 'acute brain syndrome.' DSM-III (1980) introduced 'delirium' as a specific diagnostic entity with operationalised criteria. Inouye (1990s) developed the Confusion Assessment Method (CAM), which transformed delirium detection from expert-dependent to bedside-achievable. The HELP programme (1999) demonstrated that delirium could be prevented, shifting the paradigm from reactive treatment to proactive prevention. DSM-5 (2013) placed delirium under Neurocognitive Disorders and clarified subtypes.

Despite its high prevalence and deadly consequences, delirium receives far less research funding, public awareness, and clinical training than its impact warrants. A comparison: Alzheimer's disease (affecting ~6 million Americans) receives $3+ billion annually in NIH funding, while delirium (affecting 7+ million hospitalised Americans annually) receives a fraction of that. Delirium is frequently experienced as terrifying by patients. Studies report that 50-70% of patients who recover from delirium recall at least some of their experience, including vivid visual hallucinations, paranoid beliefs, and a sense of loss of control. These memories can produce post-traumatic stress symptoms in 20-50% of survivors. For families, witnessing a loved one in delirium is deeply distressing. Seeing a previously coherent person hallucinating, confused, or combative generates fear, guilt, and helplessness. Family education and involvement in non-pharmacological interventions (reorientation, presence, reassurance) both reduces delirium severity and helps family members cope. Ageism contributes to delirium being overlooked. Confusion in elderly patients is often dismissed as 'normal ageing' or attributed to dementia without investigating for a new, treatable cause. This nihilistic attitude delays diagnosis and increases mortality.

Biomarker research is searching for objective markers to diagnose delirium and predict outcomes. Candidates include serum markers of neuroinflammation (IL-6, IL-8, S100B, NSE), neurodegeneration (neurofilament light chain), and cholinergic function (anticholinergic activity assays). EEG-based measures (reduced alpha power, increased delta/theta activity) show promise for diagnosis and monitoring but are not yet routine. Prevention trials are testing pharmacological agents: ramelteon, melatonin, and suvorexant for sleep-cycle normalisation; dexmedetomidine in perioperative settings; ketamine for post-cardiac surgery delirium prevention - results are mixed. The strongest evidence remains for multicomponent non-pharmacological programmes. Pathophysiology research is refining the neuroinflammation hypothesis using PET imaging with microglial activation trackers (TSPO ligands) to visualise brain inflammation in real time during delirium. The gut-brain axis and microbiome changes during hospitalisation are being explored as contributors. Technology-assisted interventions include tablet-based cognitive stimulation, virtual reality nature scenes for ICU patients, automated sleep monitoring, and electronic health record-based delirium prediction algorithms using machine learning. Post-delirium follow-up clinics are being piloted to address persistent cognitive deficits and psychological trauma.

APA. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR). APA Publishing. Sadock BJ, Sadock VA, Ruiz P. (Eds.). (2024). Kaplan & Sadock's Comprehensive Textbook of Psychiatry (11th ed.). Wolters Kluwer. StatPearls [Internet]. Delirium. NCBI Bookshelf. StatPearls Publishing. WHO. (2022). ICD-11 for Mortality and Morbidity Statistics. Geneva: World Health Organization.

StatPearls Delirium: https://www.ncbi.nlm.nih.gov/books/NBK470399/ Hospital Elder Life Program (HELP): https://www.hospitalelderlifeprogram.org AGS Beers Criteria: https://geriatricscareonline.org/toc/american-geriatrics-society-updated-beers-criteria/CL001 CAM Training Manual: https://www.hospitalelderlifeprogram.org/delirium-instruments/ WHO ICD-11 code 6D70: https://icd.who.int Note: Educational only. Not a substitute for professional care.